Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 9 749-756, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux

TL Vaughan, DC Farrow, PD Hansten, WH Chow, MD Gammon, HA Risch, JL Stanford, JB Schoenberg, ST Mayne, H Rotterdam, R Dubrow, H Ahsan, AB West, WJ Blot and JF Fraumeni Jr
Fred Hutchinson Cancer Research Center, and Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle 98109, USA.

Incidence of adenocarcinomas of the esophagus and gastric cardia has risen dramatically over the past 2 decades in the U. S., for reasons that are not yet clear. A number of common medications (e.g., calcium channel blockers, tricyclic antidepressants, and certain asthma medications) promote gastroesophageal reflux by relaxing the lower esophageal sphincter (LES). Reflux is thought to increase cancer risk by promoting cellular proliferation, and by exposing the esophageal epithelium to potentially genotoxic gastric and intestinal contents. Recent studies have suggested that calcium channel blockers may also increase cancer risk by inhibiting apoptosis. Using personal interview data from a multicenter, population-based case-control study conducted between 1993 and 1995 in three areas of the U. S., we evaluated whether the use of LES-relaxing drugs was associated with increased risk of adenocarcinomas of the esophagus and gastric cardia. Cases of esophageal adenocarcinoma (n = 293) and gastric cardia adenocarcinoma (n = 261) were compared with general population controls (n = 695). Information on additional case groups of esophageal squamous cell carcinoma (n = 221) and noncardia gastric cancer (n = 368) were also available for comparison. Overall, 27.4% of controls had used one or more of these drugs for at least 6 months, compared with 30.2% of esophageal adenocarcinoma and 23.8% of gastric cardia adenocarcinoma cases. The adjusted odds ratios (ORs) for ever use were 1.0 [95% confidence interval (CI) = 0.7-1.5] and 0.8 (95% CI = 0.5-1.1), respectively. There was little evidence of increasing risk with increasing duration of use of all LES-relaxing drugs together. We found an increased risk of esophageal adenocarcinoma among persons reporting use of asthma drugs containing theophylline (OR = 2.5; 95% CI = 1.1-5.6) or beta agonists (OR = 1.7; 95% CI = 0.8-3.8). Risks were higher among long-term users (>5 years) of these drugs (OR = 3.1; 95% CI = 0.9-10.3 and OR = 2.3; 95% CI = 0.8-7.0, respectively). In contrast, there was no evidence that the use of calcium channel blockers or other specific groups of drugs increased the risk of any of the cancers studied. These results provide reassuring evidence that the increases in incidence of adenocarcinomas of the esophagus and gastric cardia are not likely to be related to the use of LES-relaxing drugs as a group, or calcium channel blockers in particular, but they do suggest that persons treated for long-standing asthma may be at increased risk of esophageal adenocarcinoma.

This article has been cited by other articles:

				S. R. DeMeester Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment Ann. Surg. Oncol., January 1, 2006; 13(1): 12 - 30. [Abstract] [Full Text] [PDF]

				C. M. Berchtold, K.-S. Chen, S. Miyamoto, and M. N. Gould Perillyl Alcohol Inhibits a Calcium-Dependent Constitutive Nuclear Factor-{kappa}B Pathway Cancer Res., September 15, 2005; 65(18): 8558 - 8566. [Abstract] [Full Text] [PDF]

				J Lagergren Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut, March 1, 2005; 54(suppl_1): i1 - i5. [Abstract] [Full Text] [PDF]

				M. Ishikawa, J. Kitayama, S. Kazama, T. Hiramatsu, K. Hatano, and H. Nagawa Plasma Adiponectin and Gastric Cancer Clin. Cancer Res., January 15, 2005; 11(2): 466 - 472. [Abstract] [Full Text] [PDF]

				M. D. Gammon, M. B. Terry, N. Arber, W.-H. Chow, H. A. Risch, T. L. Vaughan, J. B. Schoenberg, S. T. Mayne, J. L. Stanford, R. Dubrow, et al. Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1: A Population-Based Study Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 34 - 39. [Abstract] [Full Text] [PDF]

				P. C. Enzinger and R. J. Mayer Esophageal Cancer N. Engl. J. Med., December 4, 2003; 349(23): 2241 - 2252. [Full Text] [PDF]

				L. S. Engel, W.-H. Chow, T. L. Vaughan, M. D. Gammon, H. A. Risch, J. L. Stanford, J. B. Schoenberg, S. T. Mayne, R. Dubrow, H. Rotterdam, et al. Population Attributable Risks of Esophageal and Gastric Cancers J Natl Cancer Inst, September 17, 2003; 95(18): 1404 - 1413. [Abstract] [Full Text] [PDF]

				T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Nonsteroidal Anti-inflammatory Drug Use, Body Mass Index, and Anthropometry in Relation to Genetic and Flow Cytometric Abnormalities in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 745 - 752. [Abstract] [Full Text] [PDF]

				X. Chen and C. S. Yang Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention Carcinogenesis, August 1, 2001; 22(8): 1119 - 1129. [Abstract] [Full Text] [PDF]

				K. Bani-Hani, I. G. Martin, L. J. Hardie, N. Mapstone, J. A. Briggs, D. Forman, and C. P. Wild Prospective Study of Cyclin D1 Overexpression in Barrett's Esophagus: Association With Increased Risk of Adenocarcinoma J Natl Cancer Inst, August 16, 2000; 92(16): 1316 - 1321. [Abstract] [Full Text] [PDF]

				J. Lagergren, R. Bergstrom, H.-O. Adami, and O. Nyren Association between Medications That Relax the Lower Esophageal Sphincter and Risk for Esophageal Adenocarcinoma Ann Intern Med, August 1, 2000; 133(3): 165 - 175. [Abstract] [Full Text] [PDF]

				G. M. Eisen The Burning Issue of Chronic Gastroesophageal Reflux Ann Intern Med, August 1, 2000; 133(3): 227 - 229. [Full Text] [PDF]

				R. P. Mason Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J. Am. Coll. Cardiol., December 1, 1999; 34(7): 1857 - 1866. [Abstract] [Full Text] [PDF]